Gilead and Precision BioSciences to collaborate on novel HBV therapies

| By | Drug Development, Gilead Sciences

Gilead Sciences and Precision BioSciences announced that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.

An estimated 257 million people are living with HBV infection around the world. Current HBV treatments suppress HBV viral replication but do not completely clear the virus. The presence of covalently closed circular DNA (cccDNA) enables HBV replication if treatment is stopped. Preliminary studies at Gilead using ARCUS nucleases to target HBV cccDNA in vitro have demonstrated significant activity against cccDNA and integrated HBV DNA in human hepatocytes.

“Gilead is committed to developing innovative therapies to achieve functional cure for patients with chronic hepatitis B virus infection,” said John McHutchison, MD, Chief Scientific Officer and Head of Research and Development at Gilead. “We are excited about the potential of genome editing and Precision’s ARCUS technology, which has demonstrated promising in vitro activity. We look forward to exploring this technology as an important component of our HBV cure research efforts.”

Under the terms of the collaboration agreement, Precision will be primarily responsible for the development, formulation, and preclinical evaluation of the investigational nucleases, and Gilead will be responsible for the clinical development and commercialization of potential therapies. Gilead will fully fund the research and development. Precision is eligible to receive milestone payments of up to an aggregate of $445 million and tiered royalties that go up to the mid-teens for commercial products developed through the collaboration.

Founded in 2006 and based in Research Triangle Park, North Carolina (USA), Precision BioSciences is a biotechnology company, engages in developing and commercializing therapeutics and services based on genomic molecular biology. It offers Biotherapeutics, a directed nuclease editor (DNE) therapeutic targeted to enable the in situ correction of genes responsible for human diseases; Biotools, an engineered DNE meganucleases used to engineer cell lines for disease models or optimize cell lines for the biomanufacturing of protein vaccines and therapeutics; and PlantSciences, a custom DNE meganucleases that enable site-specific engineering of row crops and biofuel feedstock.

SOURCE: gilead
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.